BPC 157 10 MG (prefilled syringes) and the broader category Peptides
It took the brand manufacturers more than two years to build enough capacity for the FDA to declare the shortages over, which happened on December 19, 2024, for Eli Lillys tirzepatide products, and February 21, 2025, for Novo Nordisks semaglutide products
Medicare Coverage of Anti-Obesity Medications (Issue Brief No
Brand-name GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are manufactured by pharmaceutical companies, undergo extensive FDA clinical trials, and are approved as finished drug products with fixed dosing options
This can be useful in managing heart-related conditions